Incidence of chemotherapy-induced XXXX with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.

@entity1 @entity390 @entity391 @entity228 @entity750 @entity1209
PURPOSE: This study aims to determine the incidence of @entity1209 (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV. METHODS: Chemotherapy-naive @entity1 receiving MEC between April 2012 and May 2013 were included. @entity1 completed a diary of the intensity of @entity390 and number of @entity391 episodes. Complete response and complete protection were assessed as secondary endpoints. RESULTS: Of 261 @entity1 included, 240 were evaluated. Median age was 64  years, 44.2  % were female and 11.2  % were aged less than 50  years; 95.3  % of @entity1 received a combination of @entity750 3 (5-HT3) antagonist   +   @entity228 as antiemetic treatment. Vomiting within 5  days of chemotherapy administration occurred in 20.8  %, @entity390 in 42  % and significant @entity390 in 23.8  % of @entity1 . An increase in the percentage of @entity1 with significant @entity390 (from 9.4 to 21.7  %) and @entity391 (from 9.2 to 16.5  %) was observed from the acute to the delayed phase. Complete response was 84.2  % in the acute phase, 77  % in the late phase and 68.9  % in overall period. Complete protection was 79.5  % in the acute phase, 68.8  % in the late phase and 62.4  % throughout the study period. Physicians estimated prophylaxis would be effective for 75  % of @entity1 receiving MEC, compared with 54.1  % obtained from @entity1 ' diary. CONCLUSION: Despite receiving prophylactic treatment, 31  % of @entity1 did not achieve a complete response and 38  % complete protection. In general, @entity390 was worse controlled than @entity391 . The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis.
